InformationT-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.TargetsLSD1 2.1 nMIn vitroT-3775440 treatment
InformationT-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.TargetsLSD1 2.1 nMIn vitroT-3775440 treatment
InformationT-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.TargetsLSD1 2.1 nMIn vitroT-3775440 treatment
InformationT-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.TargetsLSD1 2.1 nMIn vitroT-3775440 treatment
InformationTariquidar (XR9576) Tariquidar (XR9576) is a potent and selective noncompetitive inhibitor of P-glycoprotein with K d of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.In vitroTariquidar displays
InformationTariquidar (XR9576) Tariquidar (XR9576) is a potent and selective noncompetitive inhibitor of P-glycoprotein with K d of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.In vitroTariquidar displays
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,
ON-01910 is an inhibitor to PLK1 with IC50 of 9 nM. ON-01910 also inhibits PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC50 of 18–260 nM. ON-01910 shows cell killing activity against 94 different tumor cell lines with IC50 of 50–250 nM,